

Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

AMARIN CORP PLC\UK  
Form 6-K  
February 27, 2004

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUERS PURSUANT TO RULE  
13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT  
OF 1934

Dated: February 26, 2004

Commission file number 0-21392

AMARIN CORPORATION PLC  
(Exact name of Registrant as Specified in its Charter)

ENGLAND  
(Jurisdiction of Incorporation or  
organization of Issuer)

7 Curzon Street  
London W1J 5HG, England  
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files  
or will file annual reports under cover of Form 20-F or  
Form 40-F.

Form 20-F                       Form 40-F

Indicate by check mark whether the registrant by  
furnishing the information contained in this Form is  
also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes                                       No

Attachment:

Material Events

(a) Amarin Corporation Completes Asset Sale to  
Valeant Pharmaceuticals International.

This report on Form 6-K is hereby incorporated by reference in  
(a) the registration statement on Form F-3 (Registration No.  
333-104748) of Amarin Corporation plc and in the prospectus  
contained therein, (b) the registration statement on Form F-3  
(Registration No. 333-13200) of Amarin Corporation plc and in  
the prospectus contained therein and (c) the registration  
statement on Form F-3 (Registration No. 333-12642) of Amarin  
Corporation plc and in the prospectus contained therein, and  
this report on Form 6-K shall be deemed a part of each such  
registration statement from the date on which this report is

## Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

filed, to the extent not superseded by documents or reports subsequently filed or furnished by Amarin Corporation plc under the Securities Act of 1933 or the Securities Exchange Act of 1934.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMARIN CORPORATION PLC

By: /s/ Richard A B Stewart  
Richard A B Stewart  
Chief Executive Officer

Date: February 26, 2004

### Index to Exhibits

Exhibit Item	Sequentially Numbered Page
(a) Material Event description-	4

Exhibit (a)

Contact:  
Rick Stewart  
Chief Executive Officer  
Amarin Corporation plc  
Phone: +44 (0) 207 907 2442  
investor.relations@amarincorp.com

Ian Garland  
Chief Financial Officer  
Amarin Corporation plc  
Phone +44 (0) 207 907 2444  
investor.relations@amarincorp.com

AMARIN CORPORATION COMPLETES ASSET SALE TO  
VALEANT PHARMACEUTICALS INTERNATIONAL

LONDON, United Kingdom, February 26, 2004 Amarin Corporation plc (NASDAQ: AMRN) today announced that it has completed the sale of its U.S. based subsidiary, Amarin Pharmaceuticals, Inc. and a majority of its U.S. products to Valeant Pharmaceuticals International (Valeant) (NYSE: VRX). The terms of the transaction

## Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

were substantially as previously announced on February 12. Under the terms of the merger, Amarin Pharmaceuticals, Inc. will become a wholly owned subsidiary of Valeant Pharmaceuticals International.

Amarin also announces that it has settled its financial obligations to Elan under the terms announced on February 12, 2004.

For press releases and other corporate information, visit our website at <http://www.amarincorp.com>.

Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties which may cause the Company's actual results in future periods to be materially different from any performance suggested herein. Such risks and uncertainties include, without limitation, the uncertainty of entering into and consummating a definitive agreement on terms acceptable to the parties, the inherent uncertainty of pharmaceutical research, product development and commercialization, the impact of competitive products and patents, as well as other risks and uncertainties detailed from time to time in periodic reports. For more information, please refer to Amarin Corporation's Annual Report for 2002 on Form 20-F and its Form 6-Ks as filed with the U.S. Securities and Exchange Commission. Amarin Corporation assumes no obligation to update information on its expectations.